Healios K.K. (HLOSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Healios K.K. (HLOSF) with AI Score 47/100 (Weak). Healios K. K. is a biotechnology company focused on regenerative medicine. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Healios K.K. (HLOSF) Healthcare & Pipeline Overview
Healios K.K., a biotechnology firm based in Japan, specializes in the research, development, and commercialization of cell therapy and regenerative medicine products. Its pipeline focuses on iPSC-derived therapies for conditions like age-related macular degeneration, metabolic liver disease, ischemic stroke, acute respiratory distress syndrome, and solid tumors.
Investment Thesis
Healios K.K. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology companies. The company's focus on iPSC-derived regenerative medicines offers significant potential in addressing unmet medical needs across various therapeutic areas. A key value driver is the successful clinical development and commercialization of its lead candidates, particularly HLCM051 for ischemic stroke and ARDS. Upcoming clinical trial results and regulatory milestones represent potential catalysts. However, the company's negative profit margin of -2131.7% and gross margin of -374.0% highlight the significant financial challenges and reliance on future product revenues or partnerships. The company's high beta of 1.54 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.32 billion reflects investor valuation of Healios K.K.'s future potential in the regenerative medicine market.
- Negative P/E ratio of -18.74 indicates the company is currently unprofitable, common for biotechnology firms in the development stage.
- Profit margin of -2131.7% demonstrates substantial losses due to high R&D expenses and limited product revenue.
- Gross margin of -374.0% suggests that the cost of goods sold exceeds revenue, indicating operational inefficiencies or early-stage product pricing strategies.
- Beta of 1.54 implies the stock is more volatile than the market, reflecting the speculative nature of biotechnology investments.
Competitors & Peers
Strengths
- Innovative iPSC technology platform.
- Diverse pipeline of regenerative medicine products.
- Strategic collaborations with research institutions.
- Experienced management team.
Weaknesses
- High R&D expenses and negative profitability.
- Reliance on successful clinical trial outcomes.
- Limited commercialization experience.
- Small employee base.
Catalysts
- Upcoming: Clinical trial results for HLCM051 in ischemic stroke and ARDS.
- Upcoming: Regulatory submissions for HLCM051 in key markets.
- Upcoming: Progress in the development of HLCR011 and HLCR012 for age-related macular degeneration.
- Ongoing: Expansion of manufacturing capabilities to support product commercialization.
- Ongoing: Strategic partnerships for product development and market access.
Risks
- Potential: Clinical trial failures or delays.
- Potential: Regulatory rejection of product submissions.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: High R&D expenses and negative profitability.
- Ongoing: Dependence on future product revenues or partnerships.
Growth Opportunities
- Expansion of HLCM051 for Ischemic Stroke and ARDS: HLCM051 represents a significant growth opportunity for Healios K.K. The market for stroke and ARDS treatments is substantial, with a growing need for effective therapies. Successful clinical trials and regulatory approval could lead to significant revenue generation. The global stroke treatment market is projected to reach billions of dollars by 2030, while the ARDS market is also expected to grow substantially due to aging populations and increasing prevalence of respiratory illnesses.
- Development of HLCR011 and HLCR012 for Age-Related Macular Degeneration (AMD): The development of iPSC regenerative medicines for AMD offers a substantial growth opportunity, addressing a significant unmet need in the aging population. The global AMD market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of the disease. Successful clinical trials and commercialization of HLCR011 and HLCR012 could establish Healios as a key player in the ophthalmology market.
- Advancement of HLCL041 for Metabolic Liver Disease: HLCL041 targets metabolic liver disease, a growing health concern worldwide. The market for liver disease treatments is expanding, driven by factors such as rising rates of obesity and diabetes. Successful development and commercialization of HLCL041 could provide Healios with a valuable asset in the metabolic disease space, addressing a market projected to reach billions of dollars by the end of the decade.
- Exploration of HLCN061 for Solid Tumors: The development of HLCN061 for solid tumors represents a longer-term growth opportunity for Healios. The oncology market is one of the largest and most competitive in the pharmaceutical industry. Healios's approach to cancer immunotherapy using eNK cells, in collaboration with Hyogo Medical University, could offer a novel treatment option for various solid tumors, providing a potential entry point into this lucrative market.
- Strategic Partnerships and Collaborations: Healios can leverage strategic partnerships and collaborations to accelerate its growth and expand its market reach. Collaborations with pharmaceutical companies, research institutions, and other biotechnology firms can provide access to funding, technology, and expertise. These partnerships can also facilitate the development and commercialization of Healios's products in new markets, enhancing its overall growth trajectory.
Opportunities
- Expanding market for regenerative medicine.
- Potential for breakthrough therapies in unmet medical needs.
- Strategic partnerships for product development and commercialization.
- Geographic expansion into new markets.
Threats
- Regulatory hurdles and approval delays.
- Competition from established pharmaceutical companies.
- Technological advancements by competitors.
- Financial risks associated with drug development.
Competitive Advantages
- Proprietary iPSC technology platform.
- Strong intellectual property portfolio covering its cell therapy products.
- Strategic partnerships with leading research institutions.
- First-mover advantage in specific regenerative medicine applications.
About HLOSF
Healios K.K., established in 2011 and headquartered in Tokyo, Japan, is a biotechnology company focused on pioneering cell therapy and regenerative medicine. Originally named Retina Institute Japan, K.K., the company rebranded as Healios K.K. in September 2013, signaling its broader focus beyond retinal therapies. Healios is dedicated to the research, development, manufacture, and sale of regenerative medicine products across Japan, Europe, and the United States. Its core focus lies in induced pluripotent stem cell (iPSC) technology. Healios is developing a range of cellular and tissue-based products, including HLCR011 and HLCR012 for age-related macular degeneration, HLCL041 for metabolic liver disease, HLCM051 for ischemic stroke and acute respiratory distress syndrome (ARDS), and HLCN061 for solid tumors. The company also has a joint research agreement with Hyogo Medical University focusing on cancer immunotherapies for mesothelioma using eNK cells. Healios operates with a team of 65 employees under the leadership of CEO Tadahisa S. Kagimoto.
What They Do
- Research and develop cell therapy products.
- Manufacture regenerative medicine products.
- Sell cell therapy and regenerative medicine products in Japan, Europe, and the United States.
- Develop iPSC regenerative medicines for age-related macular degeneration.
- Develop iPSC regenerative medicines for metabolic liver disease.
- Develop regenerative medicines for ischemic stroke and acute respiratory distress syndrome.
- Develop regenerative medicines for treating solid tumors.
- Engage in joint research on cancer immunotherapies.
Business Model
- Develop and patent novel cell therapy and regenerative medicine technologies.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval for its products in key markets.
- Manufacture and commercialize approved products directly or through partnerships.
Industry Context
Healios K.K. operates within the rapidly evolving regenerative medicine sector, which is projected to experience significant growth driven by advancements in cell therapy and gene therapy technologies. The competitive landscape includes companies like AVCTF (American Vanguard Corp), BOVNF (BiondVax Pharmaceuticals Ltd), CLVLY (Clinuvel Pharmaceuticals Ltd), CMVLF (Candel Therapeutics Inc), and CRLBF (Catalent Inc), each pursuing different approaches to regenerative medicine and cell therapy. Healios's focus on iPSC-derived therapies positions it within a specific niche of this broader market, with potential advantages in scalability and consistency compared to other cell sourcing methods.
Key Customers
- Hospitals and medical centers.
- Specialty clinics focused on regenerative medicine.
- Patients suffering from targeted diseases (e.g., AMD, stroke, liver disease).
- Research institutions and universities (through collaborations).
Financials
Chart & Info
Healios K.K. (HLOSF) stock price: Price data unavailable
Latest News
No recent news available for HLOSF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLOSF.
Price Targets
Wall Street price target analysis for HLOSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HLOSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tadahisa S. Kagimoto
CEO
Tadahisa S. Kagimoto is the CEO of Healios K.K. His background includes extensive experience in the biotechnology and healthcare sectors. Kagimoto's expertise spans strategic planning, business development, and product commercialization. He has been instrumental in guiding Healios K.K.'s focus on regenerative medicine and iPSC-based therapies. His leadership is focused on driving innovation and expanding the company's global presence in the cell therapy market. Kagimoto is responsible for overseeing the company's research and development efforts, as well as its manufacturing and sales operations.
Track Record: Under Tadahisa Kagimoto's leadership, Healios K.K. has advanced its pipeline of regenerative medicine products, including HLCM051 for ischemic stroke and ARDS, and HLCR011 and HLCR012 for age-related macular degeneration. He has also overseen the company's strategic collaborations with research institutions and pharmaceutical companies. Kagimoto has been focused on securing regulatory approvals for Healios's products in key markets, as well as expanding the company's manufacturing capabilities.
HLOSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Healios K.K. (HLOSF) may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing financial distress, or choose not to comply with the listing requirements of higher tiers. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HLOSF.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- Lack of regulatory oversight compared to major exchanges.
- Potential for fraud or manipulation due to limited transparency.
- Higher risk of delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has a website and provides some information about its business.
- Healios K.K. is incorporated and has a registered office in Japan.
- The company has a CEO and a management team.
- Healios K.K. has a pipeline of regenerative medicine products in development.
- The company has strategic collaborations with research institutions.
Common Questions About HLOSF
What does Healios K.K. do?
Healios K.K. is a biotechnology company focused on developing and commercializing cell therapy and regenerative medicine products. The company's core technology is based on induced pluripotent stem cells (iPSCs), which are used to develop therapies for a range of diseases, including ischemic stroke, acute respiratory distress syndrome (ARDS), age-related macular degeneration (AMD), and metabolic liver disease. Healios aims to address unmet medical needs by providing innovative and effective regenerative medicine solutions.
What do analysts say about HLOSF stock?
As of March 16, 2026, there is no readily available analyst consensus on HLOSF due to its OTC listing and limited coverage. Key valuation metrics, such as the negative P/E ratio, reflect the company's current unprofitability. Growth considerations revolve around the successful clinical development and commercialization of its pipeline products, particularly HLCM051. Investors should conduct their own thorough research and consider the risks associated with investing in early-stage biotechnology companies.
What are the main risks for HLOSF?
The main risks for Healios K.K. include the inherent uncertainties associated with drug development, such as clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's high R&D expenses and negative profitability also pose financial risks. Additionally, as an OTC-listed stock, HLOSF carries risks related to limited liquidity, transparency, and regulatory oversight. Investors should carefully consider these risks before investing in HLOSF.
What are the key factors to evaluate for HLOSF?
Healios K.K. (HLOSF) currently holds an AI score of 47/100, indicating low score. Key strength: Innovative iPSC technology platform.. Primary risk to monitor: Potential: Clinical trial failures or delays.. This is not financial advice.
How frequently does HLOSF data refresh on this page?
HLOSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HLOSF's recent stock price performance?
Recent price movement in Healios K.K. (HLOSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative iPSC technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HLOSF overvalued or undervalued right now?
Determining whether Healios K.K. (HLOSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HLOSF?
Before investing in Healios K.K. (HLOSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.